Akari Therapeutics (NASDAQ:AKTX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a research report sent to investors on Monday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Akari Therapeutics Stock Performance

AKTX opened at $0.93 on Monday. Akari Therapeutics has a 1 year low of $0.85 and a 1 year high of $4.40. The stock’s 50 day simple moving average is $1.13 and its 200 day simple moving average is $1.87.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.